Metabolix, Inc.  

(Public, NASDAQ:MBLX)   Watch this stock  
Find more results for MBLX
-0.05 (-2.32%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.94 - 2.08
52 week 1.07 - 7.68
Open 1.98
Vol / Avg. 6,161.00/41,401.00
Mkt cap 54.66M
P/E     -
Div/yield     -
EPS -1.03
Shares 27.33M
Beta 2.97
Inst. own 10%
Nov 12, 2015
Metabolix Inc at Drexel Hamilton Micro-Cap Investor Forum
Nov 10, 2015
Q3 2015 Metabolix Inc Earnings Call - Webcast
Nov 10, 2015
Q3 2015 Metabolix Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -824.82% -956.00%
Operating margin -829.62% -958.18%
EBITD margin - -940.07%
Return on average assets -95.65% -107.34%
Return on average equity -115.15% -136.59%
Employees 68 -
CDP Score - -


21 Erie St
CAMBRIDGE, MA 02139-4260
United States - Map
+1-617-5831700 (Phone)
+1-617-5831768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Metabolix, Inc. is an advanced biomaterials company. The Company is engaged in the business of developing and commercializing technologies for the production of polymers and chemicals in microbes and plants. It is focused on delivering solutions to the plastics industry. It has its operations in the microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science. The Company offers three lines of products: biopolymers, bio-based chemicals and crop-based technologies. Its biopolymers include performance additives and functional biodegradation products, such as I6001, I6003rp, Mirel a-PHA copolymer modifier, Mirel Micropowders and Mirel P1003, F1005 for injection molding, among others. The Company's bio-based chemicals include Bio-based GBL/BDO and Bio-based Acrylic Acid. It also develops crop-based technology to co-produce renewable industrial chemicals with bioenergy in integrated bio refineries.

Officers and directors

Robert L. Van Nostrand Chairman of the Board, Independent Director
Age: 58
Bio & Compensation  - Reuters
Joseph H. Shaulson President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Johan van Walsem Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Charles B. Haaser Chief Accounting Officer
Age: 59
Bio & Compensation  - Reuters
Oliver P. Peoples Ph.D. Chief Scientific Officer, Director
Age: 57
Bio & Compensation  - Reuters
Lynne H. Brum Vice President - Marketing and Corporate Communications
Age: 51
Bio & Compensation  - Reuters
Sarah P. Cecil General Counsel, Secretary
Age: 63
Bio & Compensation  - Reuters
Peter N. Kellogg Independent Director
Age: 59
Bio & Compensation  - Reuters
Celeste B. Mastin Independent Director
Age: 46
Bio & Compensation  - Reuters
Anthony J. Sinskey Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters